Poly Medicure Limited reported a 30.3% year-on-year surge in consolidated revenue from operations to ₹525.4 Cr in Q1FY27, driven by strong international sales and new segment contributions. However, consolidated net profit declined 8.4% to ₹85.3 Cr from ₹93.1 Cr in Q1FY26, as higher employee benefit expenses and acquisition-related costs compressed margins. The Board of Directors approved the unaudited financial results on August 7, 2026.

The filing, compliant with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, also disclosed the grant of 1,476 stock options under the Employee Stock Option Scheme 2020 and the allotment of 1,975 equity shares following option exercises. Additionally, the Board re-appointed M/s Jai Prakash & Company as Cost Auditors for FY27 and noted the resignation of Ravi Prakash, Deputy Company Secretary and Compliance Officer, effective August 10, 2026.

Financial Performance

Consolidated revenue from operations rose to ₹525.4 Cr in Q1FY27, compared to ₹403.2 Cr in the same period last year. Standalone revenue grew 12.3% to ₹431.1 Cr from ₹384.0 Cr. The company's total income stood at ₹558.8 Cr (consolidated), with other income contributing ₹33.4 Cr. The following table summarises key consolidated financial metrics for the quarter:

Note: Standalone PAT increased 0.2% to ₹88.1 Cr from ₹87.9 Cr in Q1FY26.

Operational Updates

The company assumed control over Himalayan Mineral Waters Private Limited during the quarter, consolidating its financials after the National Company Law Tribunal approved the resolution plan. Polymed Brazil LTDA acquired 100% equity in Medyneo Comercio De Produtos Para Saude LTDA for ₹34.08 lacs. The paid-up equity capital increased to ₹50,68,07,325 following ESOP allotments. International sales grew 36.7% YoY to ₹376.1 Cr, though organic growth was lower at 10.4% due to acquisitions. Europe saw a 43.8% surge in revenue to ₹187.3 Cr.

What the Numbers Show

While consolidated net profit declined on a YoY basis, the core operational strength is evident in the 30.3% revenue jump. The EBITDA margin compression from 26.7% to 24.1% reflects the impact of higher employee benefit expenses, which grew 70.6% to ₹126.9 Cr (consolidated) from ₹74.4 Cr, indicating strategic hiring or wage adjustments that are yet to fully translate into proportional bottom-line gains for the group structure. Standalone profit after tax remained resilient at ₹88.1 Cr, up from ₹87.9 Cr in Q1FY26, underscoring the strength of the core domestic business. The cardiology segment saw explosive growth of 897% to ₹28.6 Cr, led by the PendraCare acquisition.

Poly Medicure 's Managing Director has stated that the company is investing in new facilities and products with the objective of doubling its international sales. The announcement signals a deliberate strategic focus on global expansion, with the company channeling resources into both infrastructure and product development to support its international growth ambitions.

Strategic Investment in Facilities and Products

According to the Managing Director, Poly Medicure is directing investments toward new manufacturing facilities and an expanded product portfolio as part of its international growth strategy. The dual focus on capacity expansion and product innovation reflects the company's intent to strengthen its competitive positioning in global markets.

International Sales Growth Target

The MD's statement highlights the company's target to double its international sales, positioning global markets as a key growth driver. The investment in new facilities and products is being pursued as the primary lever to achieve this objective.

Key Highlights

• Poly Medicure's MD has outlined plans to double international sales
• Investments are being directed toward new manufacturing facilities
• New product development is a core component of the international expansion strategy

The Managing Director's statement underscores Poly Medicure's commitment to scaling its international business through targeted investments in infrastructure and product capabilities. The company's focus on doubling international sales reflects its broader ambition to grow its global market presence.